Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities
Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreaking GEAR Trademark (Gene Edited Antibody Resistant) Cell Therapy Platform. This acquisition positions Coeptis as a leader in innovative oncology solutions, making it an attractive opportunity for traders and investors looking for high-growth potential in the biotech sector.

What Makes GEAR-NK a Game-Changer?

GEAR-NK (Gene-Edited Antibody Resistant Natural Killer Cells) represents a first-in-class approach to optimizing cancer immunotherapy. Unlike traditional NK cells that may be neutralized when used alongside monoclonal antibodies (mAbs), GEAR-NK cells are engineered to resist antibody-based depletion. This advancement allows for a synergistic effect, enhancing the potency and efficacy of combination cancer treatments.

By integrating GEAR technology into hematopoietic stem cells (HSCs), Coeptis is also exploring improved outcomes for bone marrow transplants, offering potential breakthroughs in treating hematologic malignancies. This pioneering approach has the potential to significantly enhance patient response rates and expand the market for Coeptis' next-generation therapies.

Expert Endorsement and Market Potential

Dr. Evren Alici, a renowned expert from Karolinska Institutet and a member of COEP's Scientific Advisory Board, emphasized that GEAR-based immunotherapy offers a differentiated and highly promising strategy in cancer treatment. Specifically, the ability to co-administer NK cells with CD38-targeting mAbs for multiple myeloma treatment while minimizing "on-target/off-tumor" effects could redefine how antibody-based therapies are delivered.

Coeptis CEO Dave Mehalick stated, "The market potential of GEAR is extensive and is driven by therapeutic need. GEAR, integrated into our allogeneic cellular immunotherapy platform, has the potential to provide a beneficial, cost-effective therapeutic option available to all patients in need."

Strategic Expansion with GEAR Therapeutics, Inc.

To accelerate the commercialization of the GEAR platform, Coeptis has established GEAR Therapeutics, Inc., a majority-owned subsidiary dedicated to advancing GEAR-based cell therapies into human clinical trials. This move underscores Coeptis' commitment to maximizing the value of its newly acquired technology and positioning itself as a dominant player in next-generation cancer immunotherapies.

Potential Investment Opportunity in COEP

For investors, COEP presents a compelling growth opportunity in the rapidly evolving immunotherapy market. With exclusive rights to a novel cell therapy platform, strategic partnerships with globally recognized institutions like Karolinska Institutet, and a leadership team focused on clinical execution, Coeptis is well-positioned for long-term success.

As Coeptis progresses towards clinical proof-of-concept studies for GEAR-NK, traders and investors should keep a close watch on COEP. The potential for breakthrough therapies, combined with the expanding market for immune cell therapies, makes this stock an exciting prospect in the biotechnology sector.

Summary

Coeptis' exclusive GEAR license signals a significant advancement in immunotherapy and a prime opportunity for investors looking to capitalize on biotech innovation. As the company continues to expand its pipeline and advance towards clinical trials, COEP's stock could become a high-value asset in the healthcare sector. Stay tuned for further developments as Coeptis transforms cancer treatment with its pioneering technologies.

About VyGen-Bio, Inc.

VyGen-Bio, a majority-owned subsidiary of Vycellix, Inc., operates in both Florida and Stockholm, Sweden. Its technology platforms were developed by leading researchers at Karolinska Institutet and are part of NextGenNK, an internationally recognized center for NK cell-based cancer immunotherapies.

About COEPTIS, Inc.

COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.

The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.

Other notable biotech stocks to keep on top of radar include (NASDAQ: VRTX) Vertex Pharmaceuticals Incorporated), (NASDAQ: REGN) Regeneron Pharmaceuticals, Inc., (NASDAQ: ALNY) Alnylam Pharmaceuticals, Inc., (NASDAQ: RPRX) Royalty Pharma plc, (NASDAQ: SMMT) Summit Therapeutics Inc.

For more details, visit www.VyGen-Bio.com.

Source: https://finance.yahoo.com/news/coeptis-therapeutics-secures-worldwide-development-123400980.html

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of BURU or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://usastockreport.com/disclaimer/. UsaStockReport.com.com/ has been compensated five hundred dollars by a 3rd party Carriage Consulting Group for content distribution services on COEP for March 14th, 2025. https://usastockreport.com.com/ is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of https://usastockreport.com.com/ is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like "believes," "anticipates," "estimates," "expects," "projects," "intends," or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.https://digitalcoinstandard.com/ does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.https://digitalcoinstandard.com/ is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by https://digitalcoinstandard.com/ or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. https://usastockreport.com.com/ is not a fiduciary by virtue of any person's use of or access to this content.

Media Contact
Company Name: UsaStockReport
Contact Person: Ash K
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coeptis-inc-coep-expands-cancer-immunotherapy-portfolio-with-exclusive-gear-cell-therapy-license]
City: Frisco
State: Texas
Country: United States
Website: https://usastockreport.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.